Over the past 15 years, scientists have studied a group of pain medicines called anti-NGF drugs. These drugs were designed to block nerve growth factor (NGF), a chemical in the body that plays a role in pain.
Anti-NGF drugs were developed to reduce pain, but their benefits and risks continue to be carefully studied.
Some of these drugs helped reduce pain in many patients. However, doctors and the U.S. Food and Drug Administration (FDA) also reviewed reports of serious joint damage in some people who received these medications.
Because of these concerns, the FDA held several public advisory committee meetings to carefully review safety data and hear from medical experts.
The First Major Warning: March 12, 2012
On March 12, 2012, the FDA held a full-day Arthritis Advisory Committee meeting in Maryland to review anti-NGF drugs that were being studied for arthritis pain in people.
At this meeting, doctors discussed cases where patients developed rapid joint damage, collapse of bone beneath the cartilage, and joint destruction that sometimes required joint replacement surgery.
Dr. Bob Rappaport, an FDA director, described the seriousness of these findings by stating:
“These events are severe…they seem to be occurring in relationship to exposure to these agents.”
Doctors noted that these joint changes were not expected based on early laboratory and animal studies.
One of the most concerning observations was that joints sometimes worsened very quickly, including joints that did not appear to have severe arthritis before treatment.
Orthopedic surgeon Dr. John Kelly explained his concern:
“The thing that disturbs me most is the remote site of arthritis progression of joints that had no native OA…these events are extraordinarily high and severe.”
Experts discussed the possibility that blocking pain signals could allow people to place more stress on damaged joints without realizing it, which might contribute to faster joint breakdown.
FDA Review Continued: March 24–25, 2021
Nearly ten years later, the FDA revisited these concerns during virtual advisory committee meetings held on March 24 and March 25, 2021. These meetings included both the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
During these discussions, experts again reviewed information related to rapidly progressive osteoarthritis, unexpected joint damage, and the balance between pain relief and safety.
Dr. Maria Suarez-Almazor commented on the level of benefit seen in studies:
“At most, the efficacy is just modest…we would need to treat 10 patients just to have benefit in 1.”
This led to continued discussion about whether the degree of pain relief justified the potential risks for some patients.
Some experts also raised questions about whether anti-NGF drugs could affect how the body senses joint position and movement.
Dr. George Yancopoulos explained that nerve growth factor pathways may play a role in proprioception (knowing where your body is in space and time), which helps protect joints during normal movement:
“This may not be purely an anti-NGF-type of side effect…proprioceptor dysfunction…might contribute to the demise of the joint.”
In simple terms, this raised concern that joints could be damaged without the usual warning signs of pain or instability.
Why This Is Relevant for Librela and Solensia
Librela (for dogs) and Solensia (for cats) are also anti-NGF medications. While animals are not humans, the biologic pathway targeted by these drugs is similar across species.
For this reason, some of the same questions discussed in human medicine are now being considered in veterinary medicine, including loss of protective pain, changes in how joints are loaded during movement, and uncertainty about which patients may be at higher risk for joint-related side effects.
Dr. Michael Carome stated during the human advisory discussions:
“The occurrence of rapid joint damage with all three anti-NGF agents likely represents a class effect of these drugs.”
This reflects concern about the drug category, rather than a single product.
What This Does and Does Not Mean
These FDA discussions do not mean that anti-NGF drugs should never be used. Many patients, both human and animal, appear to experience meaningful pain relief, especially when other treatment options are limited.
At the same time, the experience in human medicine highlights the importance of careful patient selection, ongoing monitoring, and continued research into long-term safety.
Pain relief alone does not always provide complete information about what is happening inside a joint, which is why a balanced and individualized approach to treatment is important.
Final Thoughts
Anti-NGF drugs were developed to reduce pain, but their benefits and risks continue to be carefully studied.
Reviewing past FDA discussions helps veterinarians, pet owners, and clinicians better understand both the potential benefits of these medications and the questions that remain.
If you would like to read all these articles and meeting transcripts in their entirety, they can be found at the link here: https://www.dropbox.com/scl/fo/xfpn6epiqonk4q6yehgz0/AM-q5UQw6JhdwVrk8xKLnxM?rlkey=7ie4pj7obsanile13x9n7362a&st=vr6ogj4y&dl=0
drbrunke 
Leave a comment